Biogen, Eisai face down another Aduhelm refusal—this time from Japanese regulators

Biogen and Eisai’s attempt to expand controversial Alzheimer’s disease drug Aduhelm has hit a snag in another large market.

A drug evaluation panel at Japan’s health ministry has refused to approve Aduhelm in Alzheimer’s, the two companies said Wednesday.